BPMC - Blueprint's Avapritinib Shows Promise For Indolent Systemic Mastocytosis
Systemic mastocytosis - overview
Source: Blueprint
Systemic mastocytosis [SM] is characterized by an excessive buildup of mast cells, typically, in the bone marrow or skin. Mast cells mediate inflammatory responses. There are five variants of SM which are grouped in two: Indolent systemic mastocytosis [ISM] and smoldering systemic mastocytosis [SSM] | Advanced systemic mastocytosis.
Indolent systemic mastocytosis
Blueprint Medicines (BPMC) is developing avapritinib for indolent systemic mastocytosis. Indolent systemic mastocytosis, or ISM, makes up 70% of all SM cases. ISM is a less severe form of SM with median overall survival measured in